London-based AI drug discovery company BenevolentAI has entered into a merger agreement with Odyssey Acquisition, a European special purpose acquisition company (SPAC), to go public on the Euronext Amsterdam Stock Exchange (AEX).
The deal, which is expected to close in Q1 2022, is reportedly the largest ever SPAC merger in Europe and it is expected to value the combined entity at EUR 1.5 billion (USD 1.7 billion).
The deal will inject around EUR 390 million (USD 440 million) net proceeds into BenevolentAI, which will include EUR 300 million (USD 339 million) raised by Odyssey in its IPO earlier this year and EUR 135 million (USD 152 million) in private investment in public equity (PIPE) from its existing partners—AstraZeneca and Temasek—and other investors. The SPAC shareholders will receive a 23.5% stake, while PIPE investors will receive a 9.1% stake in the company.
The net proceeds of the transaction will be directed towards advancing the company’s AI platform and expanding its pipeline of over 20 drug candidates.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.